HER-2 negative + ER positive

P2, N=40, Recruiting, National Cancer Centre, Singapore | Trial completion date: Dec 2027 --> Dec 2028 | Trial primary completion date: Dec 2025 --> Dec 2026

P=N/A, N=74, Not yet recruiting, Peter MacCallum Cancer Centre, Australia | Trial completion date: Feb 2032 --> Jun 2032 | Trial primary completion date: Feb 2032 --> Jun 2032

P2, N=320, Recruiting, Pfizer | Phase classification: P1 --> P2 | Trial primary completion date: Feb 2028 --> Jul 2029

P2/3, N=316, Completed, Solti Group | Active, not recruiting --> Completed

Tumor sequencing confirmed both germline variants but showed microsatellite stability and no loss of heterozygosity, arguing against a causal role of MSH6. This case illustrates how PRS, in combination with moderate-risk variants, like those in CHEK2, may drive early-onset MBC and highlights the need to incorporate polygenic models into risk assessment and counseling.

P2, N=60, Recruiting, Hoffmann-La Roche | Active, not recruiting --> Recruiting

NST was effective across aggressive subtypes, with pCR rates comparable to those observed in clinical trials. In summary, our results highlighted the contributions of functional imaging with PET/CT and MRI to staging, treatment response assessments and surgical planning in real-world clinical practice.

In SOUND-eligible patients, axillary staging with ultrasound alone provides substantial reductions in cost, operative time, and resource utilization while supporting a less invasive, value-based approach to breast cancer care. Together with existing evidence, these findings support broader implementation of the SOUND strategy in appropriately selected populations, particularly postmenopausal patients over 50 years undergoing breast-conserving surgery for cT1N0, ER-positive, HER2-negative invasive ductal carcinoma with a negative AUS.

P3, N=11000, Active, not recruiting, University College, London | Not yet recruiting --> Active, not recruiting

Variability in EndoPredict risk classification reflects both tumor biological features and population-specific factors. These findings emphasize the importance of interpreting genomic risk scores within their clinical and demographic context and support the comparison of risk distributions across heterogeneous patient cohorts.

Within an ER+/HER2- BC cohort, higher parity seems to be associated with a higher prevalence of pure ILC. No association was found between parity and clinicopathological features of ER+/HER2- pure ILC.